The Biological Intellectual Property Protection Act of 2025 inserts a new section into the Export Control Reform Act to require licenses before exporting, reexporting, or transferring in‑country digital sequence files for synthetic DNA or RNA to foreign entities of concern. The license requirement covers sequences designed by humans or by artificial intelligence and instructs the administering Secretary to implement the rule within one year of enactment.
The bill targets the cross‑border movement of actionable genetic sequence files—binary representations of DNA/RNA—that the sponsors view as vectors for intellectual property theft and dual‑use exploitation by adversaries. For compliance officers, synthesis vendors, and research institutions, the change would layer an export control regime on top of existing biosafety and data‑sharing practices and force new screening, licensing, and recordkeeping choices for digital sequence data flows.
At a Glance
What It Does
The bill creates a new mandatory license requirement for exports, reexports, and in‑country transfers of digital sequence files for synthetic DNA/RNA to any ‘foreign entity of concern,’ and it gives the responsible Secretary one year to issue implementing rules. It excludes categories already covered by section 734.3(b) of the Export Administration Regulations.
Who It Affects
Commercial DNA/RNA synthesis providers, life‑science firms that transfer sequence files internationally, academic labs that collaborate with researchers in covered jurisdictions, and the agency that administers the Export Control Reform Act (the Secretary charged with implementation).
Why It Matters
This is a narrow but high‑impact extension of export controls from physical materials and equipment to the digital instructions that enable biological engineering. It treats sequence files as controlled commodities, which shifts compliance burdens onto digital workflows and could change how institutions share sequence data with partners abroad.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill amends the Export Control Reform Act by adding a single new section that establishes a licensing requirement on sequence data. It instructs the Secretary responsible for the statute to require a license before anyone sends, resends, or transfers within a foreign country a ‘digital sequence’ of synthetic DNA or RNA to a designated foreign entity of concern.
The statute uses concise language to capture both human‑designed and AI‑designed sequences and sets a firm one‑year deadline for the Secretary to promulgate the licensing regime.
Coverage is digital: the statute defines ‘digital sequence’ as a binary file or other digital representation that records the identity, order, and any chemical modification for each position in a DNA or RNA molecule. By focusing on the file rather than the synthesized molecule alone, the bill reaches routine file transfers—email attachments, secure FTP, cloud storage shares—and in‑country transfers that might otherwise avoid traditional export checkpoints.
The bill also spells out a technical definition of ‘synthetic DNA or RNA,’ explicitly including recombinant nucleic acids, chemically synthesized molecules that can base pair with natural nucleic acids, and molecules that result from replication of those constructs.The bill ties its geographic and counterparty scope to an existing statutory definition: ‘foreign country of concern’ is the term adopted from the Research and Development, Competition, and Innovation Act. It also defines ‘foreign entity of concern’ to include governments of those countries, persons organized under their laws, and entities owned, directed, or controlled by them.
Finally, the statute leaves one narrow doorway open: the license requirement does not apply to information covered by section 734.3(b) of the Export Administration Regulations, meaning some existing EAR exclusions will continue to govern certain categories of information or public‑domain material.Taken together, the bill converts digital sequence files into regulated export items for transactions involving designated foreign actors and forces affected organizations to build an export‑control compliance pathway for a previously low‑regulated flow of data. The Secretary’s implementing regulations will determine many practical effects—how screening is done, what exceptions or license exemptions may apply, and which downstream transfers require new paperwork—but the statute makes clear the policy intent: treat sequence data as strategically sensitive intellectual property with national security implications.
The Five Things You Need to Know
The Secretary must issue regulations within one year to require a license for export, reexport, or in‑country transfer of digital sequence files for synthetic DNA/RNA to a ‘foreign entity of concern.’, The statute explicitly covers sequences ‘designed by humans or artificial intelligence systems,’ bringing AI‑generated outputs into the export‑control perimeter.
‘Digital sequence’ is defined to mean a binary file or other digital representation that records identity, order, and any chemical modification for each nucleotide position—i.e.
the bill controls the file format itself.
The license mandate applies to in‑country transfers in addition to cross‑border exports and reexports, which broadens enforcement focus to transfers that happen inside the recipient country’s territory.
The requirement does not apply to information described in section 734.3(b) of the Export Administration Regulations, preserving presently enumerated EAR exclusions for certain categories of information.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the statute as the ‘‘Biological Intellectual Property Protection Act of 2025.’
Sense of Congress explaining the security rationale
Sets out congressional findings and the national‑security rationale for the measure—citing concerns about the People’s Republic of China’s access to U.S. data and intellectual property, military‑civil fusion, and Chinese legal obligations that could compel cooperation with intelligence activities. This section does not create rights or obligations but frames the policy intent that underpins the licensing requirement in the operative section.
New license requirement for sequence files
Adds a new section to the Export Control Reform Act requiring a license for exports, reexports, or in‑country transfers of digital sequence files for synthetic DNA/RNA to foreign entities of concern. The operative language requires the Secretary to implement the licensing regime within one year. Practically, this converts sequence files into items that must be screened and licensed when the counterparty falls within the statute’s defined categories.
Exception referencing existing EAR exclusions
Carves out information described in section 734.3(b) of the Export Administration Regulations from the new license requirement. Rather than restating or superseding existing EAR exclusions, the bill defers to them, meaning some classes of information or publicly available data will likely remain outside the new licensing net depending on how EAR 734.3(b) is parsed in implementing rules.
Definitions that set technical and counterparty scope
Defines key terms: ‘digital sequence’ (binary file representations), ‘foreign country of concern’ (adopts the statutory definition from the Research and Development, Competition, and Innovation Act), ‘foreign entity of concern’ (governments, persons organized under those countries’ laws, and entities they own/control), and ‘synthetic DNA or RNA’ (recombinant nucleic acids, chemically synthesized molecules that can base pair with natural nucleic acids, and molecules resulting from replication). These definitions determine the reach of the licensing rule and will be central to enforcement and compliance guidance.
This bill is one of many.
Codify tracks hundreds of bills on Defense across all five countries.
Explore Defense in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. national security apparatus and defense planners — the bill narrows avenues for adversary access to actionable genetic design files that could inform dual‑use development or military modernization.
- Domestic biotechnology and therapeutic developers — by creating export controls on sequence files the bill aims to reduce IP exfiltration risk and preserve competitive advantages for companies handling proprietary designs.
- Commercial DNA/RNA synthesis providers that build compliant screening programs — those vendors will be better positioned to sell secure, licensed synthesis services to customers and to certify compliance for sensitive orders.
Who Bears the Cost
- Commercial DNA/RNA sequence providers and synthesis companies — they must implement screening, recordkeeping, and licensing workflows for digital sequence orders and transfers to covered foreign entities, increasing operational costs.
- Academic and nonprofit research institutions engaged in international collaboration — the license requirement could complicate routine data sharing and slow collaborative projects with researchers connected to covered jurisdictions.
- The administration agency and enforcement bodies — the Secretary must produce regulations within a year and will need ongoing resources to administer licenses, adjudicate denials, and conduct outreach and enforcement.
- Companies using AI design tools — organizations that generate sequences with AI will need to treat many outputs as potentially controlled commodities, imposing compliance overhead on software and model developers.
Key Issues
The Core Tension
The central dilemma is protecting sensitive biological IP and dual‑use capabilities from strategic rivals while avoiding an export regime so broad that it chokes legitimate science and commerce—especially collaborative research, cloud‑based workflows, and AI‑driven design pipelines that routinely move digital sequence files across borders.
The bill draws a bright line around digital sequence files, but it leaves many compliance and operational questions to the Secretary’s implementing regulations. Definitional choices in the statute—especially what counts as a ‘digital sequence’ and the statutory catch‑all for ‘molecules that result from replication’—could sweep in downstream derived files, alignment outputs, or compressed representations.
An implementing rule will have to decide whether derivative formats, metadata, or annotated sequence files fall under the license requirement and how to treat pipeline artifacts produced by automated bioinformatics and AI systems.
The exception for information described in EAR 734.3(b) reduces the chance the law unintentionally covers material already treated as exempt, but it also imports the interpretive disputes and edge cases of EAR doctrine. The statute’s reliance on other statutory definitions—‘foreign country of concern’ from a separate R&D statute—makes the scope tied to a particular legislative rubric; that improves consistency but can create brittle coverage if geopolitical assessments change faster than statutory lists.
Finally, controlling in‑country transfers expands enforcement reach but raises practical surveillance and jurisdictional questions: how will agencies detect and prove an in‑country transfer that occurred on foreign infrastructure, and what standards will apply to service providers and platforms that may host or transmit controlled files?
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.